Back to Dashboard
MYGN · Healthcare

Myriad Genetics Inc

USA Healthcare Filing: 2026-06-30
21/100
Smart-money confidence
Bottom band — money moving out

No standout activity across the feeds we track.

Stocks scoring 0–25 beat the S&P 500 39.9% of the time over the next three months, since 2015. How we measured this →

6
hedge funds
hold it · 2 added, 1 trimmed
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s.  ·  how the score works
Market cap
$524M
Industry
Diagnostics & Research
Sector
Healthcare
Exchange
NasdaqGS
About MYRIAD GENETICS INC

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic, a tumor test that determines homologous…

Who's behind the signal
Every informed buyer we can see on MYGN, across all three feeds.
Hedge funds · 6
Citadel Advisors Increased +238%
AQR Capital Management Increased +45%
D.E. Shaw & Co Unchanged
Point72 (Steve Cohen) Decreased −75%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar. MYRIAD GENETICS INC isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
0
New positions
2
Increasing
1
Decreasing
3
Unchanged
Price History
Loading price data...
Ctrl/⌘ + scroll or pinch to zoom · drag to measure · double-click to reset Pinch to zoom · drag sideways to move through time
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Portfolio Allocation
How much of each investor's portfolio is allocated to MYRIAD GENETICS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell MYRIAD GENETICS INC or any security.

订阅每周更新

我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费,直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订 · 隐私